oral sel. IDO1 dioxygenase inhibitor
100 mg QD, in I/O combo studies for cancer
acts on apo-IDO1 displacing heme co-factor
Mol. Cancer Ther., Dec. 9, 2020
BMS, Princeton, NJ / Flexus, San Carlos, CA
linrodostat
1 min read
Bristol Myers Squibb (BMS) oral selective heme-displacing IDO1 inhibitor
Search By Structure
- OI338
- PF07059013
- AZD0364
- PF-06843195
- TP0586352
- AZD4573
- “compound 42”
- “compound 12”
- BMS-986202
- pamiparib
- linrodostat
- SAR439859
- ACT-1004-1239
- “compound 1”
Molecules of the Month
2023
2022
2021
2020